Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Neoplasm
100%
Diseases
92%
Overall Survival
86%
Hazard Ratio
84%
Magnetic Resonance Imaging
84%
Cohort Analysis
80%
Hepatocellular Carcinoma
77%
Recurrent Disease
68%
Non Small Cell Lung Cancer
65%
Breast Cancer
59%
Chemotherapy
58%
Abdominal Cancer
56%
Malignant Neoplasm
53%
Tumor
49%
Computer Assisted Tomography
48%
Radiation Therapy
48%
Odds Ratio
46%
Prevalence
45%
Prognostic Factor
40%
Liver Transplantation
40%
Progression Free Survival
39%
Cancer
39%
Survival Rate
35%
Retrospective Study
34%
Lung
33%
Adverse Event
32%
Myocardial Infarction
32%
Lymph Node Metastasis
30%
Percutaneous Coronary Intervention
30%
Lung Cancer
29%
Epidermal Growth Factor Receptor
28%
Biopsy Technique
28%
Multivariate Analysis
28%
Diabetes
27%
Positron Emission Tomography-Computed Tomography
27%
Body Mass Index
27%
Living Donor
27%
Quality of Life
27%
Chemoradiotherapy
26%
Median Follow Up
26%
Apoplexy
26%
Retrospective Cohort Study
25%
Pediatrics
25%
Radiofrequency Ablation
24%
Genetics
23%
Randomized Controlled Trial
23%
Echography
23%
Adenocarcinoma
23%
Long-Term Outcome
22%
Arm
22%
Infection
21%
Disease Free Survival
21%
Biological Marker
21%
Treatment Outcome
20%
Clinical Trial
19%
Hepatectomy
19%
Area under the Curve
19%
Cardiovascular Disease
18%
Fluorodeoxyglucose F 18
18%
Chronic Kidney Disease
18%
Observational Study
18%
Proportional Hazards Model
18%
Papillary Thyroid Cancer
18%
Colorectal Carcinoma
18%
Diabetes Mellitus
18%
COVID-19
17%
Atrial Fibrillation
17%
Maturity Onset Diabetes of the Young
17%
Cervical Cancer
17%
Placebo
17%
Surgeon
17%
Artificial Intelligence
17%
Logistic Regression Analysis
16%
Congestive Heart Failure
16%
Cardiovascular System
16%
Lymph Node
16%
Propensity Score Matching
16%
Brain Ischemia
16%
Clinical Feature
16%
Recurrence Free Survival
15%
Clinical Significance
15%
Diagnostic Performance
15%
Morbidity
15%
Silo-Filler's Disease
15%
Nonalcoholic Fatty Liver
15%
Prostate Cancer
15%
Meta-Analysis
15%
Hypertension
15%
Multiple Myeloma
15%
Surgery
14%
Acute Heart Infarction
14%
Subgroup Analysis
14%
Prediction Model
14%
Platinum
14%
Metastatic Carcinoma
14%
Injection
14%
Bleeding
13%
Carcinoma
13%
positron emission tomographic scan
13%
Oral
13%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
41%
Non Small Cell Lung Cancer
41%
Chemotherapy Regimen
40%
Malignant Neoplasm
39%
Cohort Study
34%
Adverse Event
34%
Neoplasm
34%
Overall Survival
32%
Progression Free Survival
26%
Epidermal Growth Factor Receptor
22%
Placebo
21%
Liver Cell Carcinoma
19%
Monotherapy
19%
Abdominal Cancer
17%
Breast Cancer
16%
Prevalence
16%
Recurrent Disease
15%
Heart Infarction
14%
Acute Heart Infarction
14%
Clinical Trial
14%
Cerebrovascular Accident
13%
Infection
13%
Biological Marker
13%
Platinum
11%
Maturity Onset Diabetes of the Young
11%
Congestive Heart Failure
11%
Nonalcoholic Fatty Liver
10%
Multiple Myeloma
10%
Atrial Fibrillation
10%
Cardiovascular Disease
10%
Antiplatelet
10%
Lung Cancer
10%
Cisplatin
10%
Hypertension
9%
Bloodstream Infection
9%
Pembrolizumab
9%
Solid Malignant Neoplasm
9%
Paclitaxel
9%
Retrospective Study
9%
Dexamethasone
9%
Randomized Controlled Trial
8%
Pharmacokinetic
8%
Observational Study
8%
Tolerability
8%
Metabolic Syndrome X
8%
Phase II Trials
8%
Gemcitabine
8%
Diabetes Mellitus
8%
Glucose
8%
Chronic Kidney Failure
7%
Chronic Obstructive Lung Disease
7%
Survival Rate
7%
Hepatitis B Virus
7%
Bleeding
7%
Disease Exacerbation
7%
Combination Therapy
7%
Rat
7%
Statin (Protein)
7%
Fatty Liver
6%
Colorectal Carcinoma
6%
Overactive Bladder
6%
Docetaxel
6%
Inflammation
6%
Prostate Cancer
6%
Pneumonia
6%
Gamma Urogastrone
6%
Chronic Hepatitis B
6%
Brain Ischemia
6%
Clopidogrel
6%
All Cause Mortality
6%
Lipid
5%
Chemoradiation Therapy
5%
Nanoparticle
5%
Ovary Cancer
5%
Fibrosis
5%
Uterine Cervix Cancer
5%
Phase III Trials
5%
Tumor Growth
5%
Neutropenia
5%
Epidermal Growth Factor Receptor 2
5%
Acetylsalicylic Acid
5%
Insulin
5%
Oxaliplatin
5%
Antitumor Activity
5%
Metastatic Breast Cancer
5%
Transitional Cell Carcinoma
5%
Protein Tyrosine Kinase Inhibitor
5%
Asthma
5%
Osimertinib
5%
Randomized Clinical Trial
5%
Metastatic Colorectal Cancer
5%
Antibiotics
5%